LivaNova PLC (NASDAQ:LIVN) Receives Consensus Recommendation of "Buy" from Analysts

LivaNova PLC (NASDAQ:LIVN - Get Free Report) has been assigned a consensus recommendation of "Buy" from the seven ratings firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $69.83.

A number of brokerages have issued reports on LIVN. The Goldman Sachs Group began coverage on LivaNova in a research note on Friday, October 4th. They issued a "buy" rating and a $65.00 target price for the company. Baird R W raised LivaNova from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, September 17th. Needham & Company LLC lifted their price objective on LivaNova from $72.00 to $75.00 and gave the company a "buy" rating in a research note on Wednesday, July 31st. Stifel Nicolaus lifted their price objective on LivaNova from $70.00 to $72.00 and gave the company a "buy" rating in a research note on Thursday, July 25th. Finally, Robert W. Baird upgraded LivaNova from a "neutral" rating to an "outperform" rating and lifted their price objective for the company from $55.00 to $66.00 in a research note on Tuesday, September 17th.

LivaNova Price Performance

LIVN traded up $1.28 during trading hours on Monday, hitting $53.82. The company's stock had a trading volume of 332,650 shares, compared to its average volume of 632,212. The company has a current ratio of 3.45, a quick ratio of 2.94 and a debt-to-equity ratio of 0.49. LivaNova has a 12 month low of $42.75 and a 12 month high of $64.47. The stock has a market cap of $2.91 billion, a price-to-earnings ratio of -87.55 and a beta of 1.00. The business's 50-day moving average price is $48.89 and its 200-day moving average price is $53.28.

LivaNova (NASDAQ:LIVN - Get Free Report) last issued its earnings results on Wednesday, July 31st. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.66 by $0.15. The firm had revenue of $318.60 million during the quarter, compared to analyst estimates of $305.05 million. LivaNova had a negative net margin of 1.37% and a positive return on equity of 13.77%. Sell-side analysts expect that LivaNova will post 2.58 earnings per share for the current fiscal year.

Institutional Investors Weigh In On LivaNova

Institutional investors have recently added to or reduced their stakes in the business. Diversified Trust Co grew its position in shares of LivaNova by 7.9% during the third quarter. Diversified Trust Co now owns 15,007 shares of the company's stock worth $788,000 after acquiring an additional 1,105 shares during the last quarter. Central Pacific Bank Trust Division purchased a new position in LivaNova during the 3rd quarter worth $178,000. Perceptive Advisors LLC increased its stake in LivaNova by 48.5% in the second quarter. Perceptive Advisors LLC now owns 444,000 shares of the company's stock valued at $24,340,000 after purchasing an additional 145,000 shares during the period. Driehaus Capital Management LLC increased its stake in LivaNova by 64.7% in the second quarter. Driehaus Capital Management LLC now owns 544,042 shares of the company's stock valued at $29,824,000 after purchasing an additional 213,749 shares during the period. Finally, Susquehanna Fundamental Investments LLC acquired a new position in LivaNova in the second quarter valued at $2,893,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.